Cargando…
The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co‐exposure with chemical inducers in culture
BACKGROUND: Erythroleukemia is caused by the uncontrolled multiplication of immature erythroid progenitor cells which fail to differentiate into erythrocytes. By directly targeting this class of malignant cells, the induction of terminal erythroid differentiation represents a vital therapeutic strat...
Autores principales: | Papagiannopoulos, Christos I., Theodoroula, Nikoleta F., Kyritsis, Konstantinos A., Akrivou, Melpomeni G., Kosmidou, Maria, Tsouderou, Konstantina, Grigoriadis, Nikolaos, Vizirianakis, Ioannis S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788816/ https://www.ncbi.nlm.nih.gov/pubmed/33407944 http://dx.doi.org/10.1186/s40709-020-00132-3 |
Ejemplares similares
-
miR-16-5p Promotes Erythroid Maturation of Erythroleukemia Cells by Regulating Ribosome Biogenesis
por: Papagiannopoulos, Christos I., et al.
Publicado: (2021) -
Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine
por: Chatzopoulou, Fani, et al.
Publicado: (2022) -
A Risk-Stratification Machine Learning Framework for the Prediction of Coronary Artery Disease Severity: Insights From the GESS Trial
por: Mittas, Nikolaos, et al.
Publicado: (2022) -
Invariable Ribosome Stoichiometry During Murine Erythroid Differentiation: Implications for Understanding Ribosomopathies
por: Papagiannopoulos, Christos I., et al.
Publicado: (2022) -
Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study
por: Astras, George, et al.
Publicado: (2020)